Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could be on its way to teens with numbers like these imo
Trash post. Marked it.
You repost . Don't make sense at all
Someone should go to his house or call him. He walks the red carpet works 1 day a week 2million a year salary. Offering to pay him for 10 years
Dane Andreeff Phone Number, Address, Age, Contact Info, Public ...
All Information about Dane Andreeff ; Phones. (850) 622-3353 ; Addresses. 2710 Fairway Dr, Baton Rouge, LA 70809; 4302 French Village Ave, Baton Rouge, LA
You have very good posts I will say. Being honest. Your smart. Have a nice weekend
Suppressed Image]
"DIRTY HARRY here, to underscore that as an iHub investor in ANY kind of COMPANY, you invariably have to ask yourself just ONE simple question during your FINAL DD --- as I have graciously filmed & recorded, directly ABOVE, for your personal stock TRADING edification, amusement, & otherwise enlightenme
Makes no sense.* that's a weird post
HSDT: Classic Morning-Gapper-Suckers-Play, all day long! GLAD I stayed far away. Gettin' this crap every day now. The NASDAQ, et al., are now the OTC of years past --- BEFORE the SEC, OTC, & FBI cleaned-it-up (somewhat)!!
"DIRTY HARRY here, to underscore that as an iHub investor in ANY kind of COMPANY, you invariably have to ask yourself just ONE simple question during your FINAL DD --- as I have graciously filmed & recorded, directly ABOVE, for your personal stock TRADING edification, amusement, & otherwise enlightenment."
HOD was 2.76. That was your moon blast buddy!
Where's the FUEL coming from???!!!
HSDT: Fluck!!! Off to the Moon??? Or, suckers' BAIT???
"DIRTY HARRY here, to underscore that as an iHub investor in ANY kind of COMPANY, you invariably have to ask yourself just ONE simple question during your FINAL DD --- as I have graciously filmed & recorded, directly ABOVE, for your personal stock TRADING edification, amusement, & otherwise enlightenment."
"Tell-it-like-it-is, Harry!! You gots RESPECT, Dude --- I'll tell-ya!!"
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
Up 200% pre mkt. No news
L.O.L. sink it. NOW TRY SINKING MY AMC!!!!
Gotta nibble here at $2. Ultra-Low floater. $3-4-5-$7 could happen very quickly.
No not true, that was a 175 share bidwhack @ .0004, the warrants have barely ever traded in their history, so its been impossible to accumulate a position of any even remotely decent size.
This is the entire trading history.
06/08/2022--0.09-- 700
06/08/2022--0.09-- 1
06/08/2022--0.09-- 450
06/08/2022-- 0.094--135
06/08/2022--0.08505--135
06/08/2022--0.15-- 240
06/02/2022--0.0201--2000
06/01/2022--0.10-- 1000
06/01/2022--0.10-- 1000
05/25/2022--0.10-- 2000
05/17/2022-- 0.02-- 9500
05/17/2022--0.026--14492
05/17/2022-- 0.026 10000
05/17/2022--0.029--9000
05/17/2022-- 0.029--17115
03/11/2022--0.05-- 100
02/16/2022--0.04-- 400
01/26/2022--4.07-- 100
04/27/2021--0.0004--175
04/01/2021--1.00-- 50
04/01/2021--1.00-- 100
03/26/2021-- 2.00-- 550
02/22/2021--2.50-- 250
02/18/2021-- 2.50-- 500
02/18/2021-- 2.50-- 50
02/18/2021--2.00-- 900
HSDT: Below is a pasted copy of my OWN personal notes today about this scam company (have a good laugh, Folks!):
"HSDT (NASDAQ): 6-1-22 (Wed.) news stupid (Sideshow) electric gadget makes MS cripples walk better; also, glorious global access to said silly gadget.
"Hey, last time I saw a SCAM COMPANY like this one, it was in a SIDESHOW at a local Ringling Brothers, Barnum & Bailey, CIRCUS! Right next to the Three-Headed Lady, the Dog-Faced Boy, and the Wild Man From BORNEO!!"
Only 3.8 mil shares are outstanding and we have traded 24 mil shares already!OMG
Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®
New program seeks to expand access to patients suffering from multiple sclerosis (MS)
NEWTOWN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (“PTAP”), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (“PoNS”) Therapy at a significantly reduced price. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from multiple sclerosis (“MS”) and is available by prescription only.
“In April, we announced that the first patients in the United States had purchased the PoNS device on a cash pay basis and begun treatment. We are also offering an opportunity for MS patients to be treated with PoNS Therapy™ through our previously announced Therapeutic Experience Program (“TEP”), gathering important clinical evidence in a real-world environment while we pursue reimbursement from third-party payers and CMS. Our goal is to bring treatment to as many qualifying patients as possible and we are proud to introduce our Patient Therapy Access Program for potential first-time users,” stated Dane Andreeff, President and Chief Executive Officer of Helius.
“With the proper prescription and a letter of medical necessity, people struggling with MS in the U.S. will be able to access PoNS Therapy at a greatly reduced price. We believe this program will accelerate the adoption of PoNS Therapy and help to establish PoNS as the standard of care for MS patients with gait deficit. PTAP participants will also be invited to join Helius’s upcoming registry program, which is designed to collect important health economic information to establish the value of PoNS on key therapeutic outcomes and will complement the data gleaned through TEP,” concluded Mr. Andreeff.
The PTAP is currently available and expected to run through December 31, 2022.
No idea...I posted on it over 2 years ago...
Hi Georgie. Any news Re : $HSDT ? TIA GLTA $HSDT
$HSDTW: Only at $0.0004
Damn thats pretty cheap.
Count me IN
GO $HSDTW
Man no respect for good stock, but chinese pos goes through the roof imo
HSDT > Helius Medical Technologies shares are trading higher after it was reported the FDA authorized marketing authorization of the Portable Neuromodulation Stimulator to Helius Medical.
JUST IN: $HSDT Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and Clearance of the PoNS(TM) Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis
NEWTOWN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has received a request for additional information ...
In case you are interested HSDT - Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and Clearance of the PoNS(TM) Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis
NEWS: $HSDT Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board
NEWTOWN, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the formation of a Multiple Sclerosis (“MS”)...
Find out more HSDT - Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board
BREAKING NEWS: $HSDT Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS(TM)) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Mode
NEWTOWN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the publication of an important, peer-reviewed study titl...
In case you are interested HSDT - Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS(TM)) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Mode
Well, about 25% held by insiders and institutions. But it is a sleeper breakout IMO
HSDT on a multi week breakout....nothing huge but almost half of the outstanding shares are owned by institutions. Could spike in the next few days.
Seems something is brewing... waiting to see PR soon.
The company just released prelim numbers for 2019. Revenue was $1.5MM (the low end of their already once downgraded range), and this was with 6 clinics in Canada, many which only came on-board late in the year.
They have since added 7 more clinics covering 9 more locations (no details on where), and will be requesting clearance in Canada for Multiple Sclerosis indication, in addition to mmTBI (the only official indication today).
They also said they will submit FDA de-novo for MS later this year based on an existing body of evidence. Hopefully their discussions with FDA are well informed enough that they don't expect the same rejection they got for mmTBI.
Still, encouraging progress out of Canada. I would still love to see more official statements from the PT community or patients about their results. My last post about the MS patient was very encouraging. There should be dozens more like it if the results are real.
Still largely sitting on the sidelines here, ready to jump in if things look very positive.
A recent article about PoNS use to aid a man with MS:
https://calgary.ctvnews.ca/calgary-man-with-multiple-sclerosis-sold-on-tongue-tingler-neural-therapy-1.4730971
The company recently announced another clinic that will offer PoNS treatment, bringing the total to 8 in Canada, slightly ahead of the number they anticipated to have by the end of 2019. However, the latest clinic is a one-physician outfit, 40 miles from the largest city on Vancouver island, with a population of under 100,000 people, so it's hardly a "material event" worthy of an 8K.
If the patient outcomes from the initial larger clinics are as good as the company has been touting, the PT community will surely pick up on it and more clinics will sign-on. If they fail to get the word out and build momentum by the end of summer 2020, then I'm inclined to think it's not going happen. And if there is no commercial traction in Canada, then a US FDA approval would be a non-event.
If, on the other hand, we do get strong testimonials from patients and physicians, and the company can get their devices into more Canadian clinics, it would bode well for the stock (finally) and FDA approval would be an inflection point.
For now, I'm watching this space with a speculative position (well into the red), and ready to invest more should we see encouraging progress.
White Diamond is a Hedge form that love shorting stocks. Those Jokers are all over small caps especially those small caps that has good meat on its bone. White Diamond hedge a lot of stocks. also especially if that had a great run. remind me of clay and his goonies.
I agree. Like mention the PoNS device was passed in Canada. The Helius need to find a way to make it prospers, so they would need to do those offerings which might kill the share price for good. I don't think the will last another year without a Partner, not with these class action lawyers on their trail.
White Diamond has written another bearish article about HSDT on SA. I have provided an alternative viewpoint. https://seekingalpha.com/article/4314666-helius-medicals-new-report-provides-evidence-device-is-ineffective#comments
That's right.. FDA wanted assurance (that even this latest independent study did not provide) that physical therapy alone was not yielding the same improvement in balance than PT together with the PoNS.
I find it a little far-fetched to suggest PT alone may have been the main factor in the improvements given that all patients had already been undergoing PT in the past and were no longer seeing any improvements. Perhaps the PT regime was very different when done together with PoNS?
Either way, the company is all over this, and unless the new trials that they've agreed with FDA do not yield the same results, I would expect FDA clearance is in the bag. I just won't be very soon. But in the meantime, Canadian market is their litmus test.. if results are strong there, then they really have something unique. More indications and larger markets (US, EU) would be outstanding.
This PoNS Neurostimulation Device is going to pass the FDA submission.
So what are they trying to say, the patients were reaching some of these goals without the use of the PoNS neurostimulation device. The difference is that all of these patients didn't start the PoNS neurostimulation not until after 12 months after their brain injuries, then they started the program. IMO, I guess the FDA wanted half in the study to be treated with the PoNS neurostimulator device and the other half to be treated with Physical Therapy sections not using the PoNS Device. Make sense. Next complete a trial study of Patients whom have completed Physical Therapy and enroll them into the PoNS neurostimulator device Clinical study and see how well they benefited from using the PoNS device after going thru PT. What percentage of patients benefited from the PoNS Device, and what percentage of patients did not benefit from the device.
Then on the other hand I can see while Helius Medical Technologies Inc sent in their NDA for PoNS Device because they use Patients 12 months after their injuries and not before. IMO the reason why the FDA did not have enough evidence to support Helius study of the PoNS. Maybe if they would've started the study from start of traumatic injuries mild to moderate injuries, in both physical therapeutic to using the PoNS Device and a study of Patient using PT without PoNS device. Helius Medical Technologies inc would probably have an FDA Approval for the PoNS neurostimulation Device.
Please, Correct me if I'am wrong.
The third-party study is definitely helping IMO, though that particular study did also have a statement in the conclusion that they could not rule out that the improvements were not related to the PT alone. This was FDA's main gripe, but given that all these patients had been doing PT before and were no longer improving, I find it hard to imagine PT (or placebo effect) was the sole reason for the dramatic improvements.
With the existing Canadian clinics alone, by their own estimates, they should achieve annual revenues of $7MM. If traction continues and they get more clinics and actual results yield the same outcomes as the studies, then an FDA approval would be huge. But Canada alone can easily make this a profitable business. Time will tell .. so far not much press out of the Canadian clinics...
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
266
|
Created
|
09/02/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |